Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.

You are here:Home-Chemical Inhibitors & Agonists-JAK/STAT Signaling-JAK-TAK-279
TAK-279

Chemical Structure : TAK-279

CAS No.: 2272904-53-5

TAK-279 (Zasocitinib, TAK279, NDI-034858)

Catalog No.: PC-20516Not For Human Use, Lab Use Only.

NDI-034858 (Zasocitinib, TAK-279) is a potent, selective and allosteric TYK2 inhibitor, targets TYK2 JH2 domain with binding KD of 3.8 pM.

Packing Price Stock Quantity
2 mg $188 In stock
5 mg $328 In stock
10 mg $528 In stock
25 mg $898 In stock
50 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

TAK-279 (Zasocitinib, NDI-034858) is a potent, selective and allosteric TYK2 inhibitor, targets TYK2 JH2 domain with binding KD of 3.8 pM.
TAK-279 exhibites hignly potent cellular pSTAT4 IL12 PBMC IC50 of 6.7 nM.
TAK-279 displays functional selectivity over JAK1, JAK2, and JAK3.
TAK-279 inhibits IFNα-stimulated phosphorylation of STAT3 in CD3-positive T-cells as well as IFNα-stimulated CXCL10 production in whole blood with IC50s of 1.7 and 22 nM, respectively.
TAK-279 inhibits IL23-stimulated phosphorylation of STAT3 in human CD161 + CD3 + TH17 cells with an IC50 of 3.7 nM.
TAK-279 inhibits IFNα-stimulated CXCL10 production  in mouse and rat whole blood with IC50 of 347 and 91 nM, respectively.
TAK-279 also inhibits IL12-IL18-stimulated induction of IFNγ in whole blood with IC50 of 48 nM.
TAK-279 (30 mg/kg) demonstrated dose-dependent suppression of IL12/IL18-induced IFNγ production in rat in vivo PD model.

Physicochemical Properties

M.Wt 460.50
Formula C23H24N8O3
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

N-((1R,2R)-2-methoxycyclobutyl)-7-(methylamino)-5-((2-oxo-2H-[1,2'-bipyridin]-3-yl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide

References

1. Patent WO2019023468 A1. Pyrazolopyrimidines as TYK2 inhibitors and their preparation.
2. Leit S, et al. J Med Chem. 2023 Jul 10. doi: 10.1021/acs.jmedchem.3c00600.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: